metabion has increased its global production capacity for diagnostic and newly introduced therapeutic oligonucleotides and derivatives thereof to support the rising demand in Europe and worldwide.
Over the last two years, the company has planned, built and established a state-of-the-art oligonucleotide manufacturing facility dedicated to manufacture small-, mid- and large-scale oligonucleotide components for in vitro diagnostics (IVD)/analyte-specific reagents (ASRs)oligonucleotides as well as mid-/large-scale oligos for R&D and therapeutic applications.
The investment is in the double-digit million EURO range and includes ISO 8 and 7 classified state-of-the-art clean room areas. Applied and certified standards are ISO 9001:2015, ISO 13485:2016 and EXCiPACT GMP/GDP:2021.
"With this investment, we are strengthening our CMO segment and are committed to further expanding our growth area of business," said Dr Regina Bichlmaier, CEO of metabion. "At the same time, we are responding to an increasing demand for highly customised diagnostic solutions including packaging/kitting/OEM services and supporting early stage oligonucleotide-based drug development from lead discovery and optimisation to pre-clinical development into clinical phase I and II."
Bichlmaier continued: "We are proud to say, that our newly established and outstanding state-of-the art production site East of Munich will allow us to deliver “metabion best value” for small-, mid- and large-scale oligonucleotide requirements with regard to expertise, capacities, customisation and flexibility.”
"We want to drive growth in the custom oligonucleotide business with our strong and metabion inbuilt customer focus," said Dr Heike Koepf, Head of Sales and Quality Management. "In doing so, we aim to intensify our collaboration with customers in Europe and expand our product portfolio to globally interested parties”.
